EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy

Chi Hun Song, Minchan Jeong, Hyukmin In, Ji Hoe Kim, Chih-Wei Lin, Kyung Ho Han iD

Antibodies · 03.11.2023 · 12 (4) · 72

DOI: 10.3390/antib12040072 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 03.11.2023. Verfasst von Chi Hun Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2023 Hannam University Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In cancer treatment, the first-generation, cytotoxic drugs, though effective against cancer cells, also harmed healthy ones. The second-generation targeted cancer cells precisely to inhibit their growth. Enter the third-generation, consisting of immuno-oncology drugs, designed to combat drug resistance and bolster the immune system’s defenses. These advanced therapies operate by obstructing the uncontrolled growth and spread of cancer cells through the body, ultimately eliminating them effectively. Within the arsenal of cancer treatment, monoclonal antibodies offer several advantages, including inducing cancer cell apoptosis, precise targeting, prolonged presence in the body, and minimal side effects. A recent development in cancer therapy is Antibody-Drug Conjugates (ADCs), initially developed in the mid-20th century. The second generation of ADCs addressed this issue through innovative antibody modification techniques, such as DAR regulation, amino acid substitutions, incorporation of non-natural amino acids, and enzymatic drug attachment. Currently, a third generation of ADCs is in development. This study presents an overview of 12 available ADCs, reviews 71 recent research papers, and analyzes 128 clinical trial reports. The overarching objective is to gain insights into the prevailing trends in ADC research and development, with a particular focus on emerging frontiers like potential targets, linkers, and drug payloads within the realm of cancer treatment.

Schlagwörter

Stichwörter der Autor:innen

antibody drug conjugatesconjugationlinkermonoclonal antibodypayload

Autor:innen und Institutionen

  • Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea.
  • Institute of Biochemistry and Molecular Biology, China Medical University, Taichung 406, Taiwan.

ORCID-Profile: Kyung Ho Han

Förderung

  • 2023 Hannam University Research Fund

Zitieren

APA

Song, C. H., Jeong, M., In, H., Kim, J. H., Lin, C. W., & Han, K. H. (2023). Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies, 12(4), 72. https://doi.org/10.3390/antib12040072

Vancouver

Song CH, Jeong M, In H, Kim JH, Lin CW, Han KH. Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies. 2023;12(4):72. doi:10.3390/antib12040072

BibTeX
@article{Song2023,
  author = {Song, Chi Hun and Jeong, Minchan and In, Hyukmin and Kim, Ji Hoe and Lin, Chih-Wei and Han, Kyung Ho},
  title = {Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy},
  journal = {Antibodies},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {72},
  doi = {10.3390/antib12040072}
}
Kostenlos starten →